In direct compression of Puqing Zhili Powder Veterinary Grade API into veterinary tablets, the input powder is first passed through a 0.8 mm vibratory sieve and conditioned at 20–25 °C and ≤40% RH before dry blending. Published data for this specific configuration is limited; the ranges below are derived from standard veterinary pre-formulation screening under VICH GL1 and VICH GL2, not from a proprietary master file. The dry blend contains API equivalent to the designated active marker per 750 mg tablet, microcrystalline cellulose 40–60% w/w, lactose monohydrate 20–30% w/w, croscarmellose sodium 2–5% w/w, and magnesium stearate 0.5–1.0% w/w. Compression is performed on a 16-station rotary tablet press at 35–45 kN main compression force; granulation is required if loss on drying exceeds 5.0% or if capping occurs above 60% RH in the compression suite. Disintegration is measured according to USP <701> and remains below 15 min in 0.1 M HCl at 37 ± 2 °C. Content uniformity follows USP <905>/Ph. Eur. 2.9.40 with an acceptance value of ≤15.0 for a 10-unit sample. Tablet friability is controlled to ≤1.0% under USP <1216>. Aqueous ethylcellulose film coating may be applied for bitter-taste masking, but the coating must not shift dissolution at 45 min by more than 10% relative to the uncoated core. Mass variation on a 16-station press is held below 2.0% when feeder paddle speed is maintained at 20–30 rpm and die fill depth is not adjusted by more than ±0.15 mm.

What Limits Terminal Sterilization Windows for Injectable Grades of Puqing Zhili Powder?

Because terminal sterilization remains the narrowest processing window for injectable-grade Puqing Zhili Powder Veterinary Grade API, the first pre-formulation screen evaluates thermal stability at 121 °C for 15 min. If the marker compound shows less than 95% recovery under forced degradation, the batch is transferred to an aseptic processing line conforming to EU GMP Annex 1 Grade A/B. The bulk solution is prepared in a stainless steel vessel with a bottom-mounted high-shear mixer and is passed through a 0.45 μm polypropylene prefilter followed by a 0.22 μm PVDF membrane filter to achieve a bioburden below 10 CFU/100 g before sterile filtration. The formulation uses a citrate or phosphate buffer at pH 5.5–7.0, API concentration adjusted to the labeled dose, typically 10–50 mg/mL for the marker compound, sodium chloride 0.7–0.9% w/v, and benzyl alcohol 1.0–2.0% v/v in multi-dose vials. Sterility testing is conducted according to USP <71>/Ph. Eur. 2.6.1 by membrane filtration, and bacterial endotoxin limits are set according to USP <85>/Ph. Eur. 2.6.14 at ≤0.5 EU/mg for intravenous or ≤1.0 EU/mg for intramuscular administration. Particulate matter is controlled by USP <788> with a limit of 25 particles per container at ≥10 μm and 3 particles per container at ≥25 μm. The osmolality of the finished injection is adjusted to 280–320 mOsm/kg for intramuscular use. The limiting factor is insoluble plant-derived polysaccharide carryover; if particle counts exceed the limit, the batch is re-filtered through a charged depth filter and retested. The injection is filled in amber Type I glass vials under nitrogen overlay with residual oxygen below 2.0% v/v to protect oxygen-sensitive fractions.

For low-dose capsule filling of Puqing Zhili Powder Veterinary Grade API, dry pre-milling is set so that 90% of the powder passes a 250 μm sieve and bulk density is held between 0.45 g/mL and 0.65 g/mL. The milled API is blended with lactose monohydrate and 0.5% w/w magnesium stearate in a V-blender for 15 min; over-mixing beyond 30 min reduces dissolution and is avoided. The blend is filled into hard gelatin or hypromellose capsules on a dosator or tamping-pin machine to deliver the labeled marker dose per capsule. Weight variation is controlled by USP <905> with an acceptance value of ≤15. The filled capsules are inspected by a metal detector with a 1.0 mm ferrous and 1.5 mm non-ferrous test standard, then packaged in HDPE bottles containing desiccant when API moisture is specified below 5.0%.

Assessing Sedimentation Half-Life and Viscosity in Drinking-Water-Soluble Powder Reconstitution

After reconstitution in drinking-water systems, powders containing Puqing Zhili Powder Veterinary Grade API show two failure modes: rapid sedimentation and nipple-drinker clogging from swelling polysaccharides. The dry blend is therefore prepared on a spray-dried lactose carrier with a median particle size D50 60–120 μm and includes 0.1–0.2% w/w colloidal silicon dioxide to prevent caking. The powder is packed into foil-lined laminate sachets under ≤30% RH; reabsorption of moisture above 5.0% causes incomplete dispersion. The reconstituted solution is prepared by adding 100 g of powder to 100–200 L of tap water at 25 ± 5 °C, giving a final concentration of 0.5–1.0 g/L in the drinking line. The pH is adjusted with citric acid/sodium citrate to pH 4.0–6.0 to maintain solubility and reduce microbial growth over the 24 h consumption period. Sedimentation half-life is tested with a 500 mL graduated cylinder and should exceed 30 min; viscosity is measured on a rotational viscometer at 25 °C and should remain below 20 mPa·s at 100 s⁻¹ shear rate to avoid drinker line blockage. The reconstituted solution is monitored for total aerobic count below 10² CFU/mL under the veterinary GMP requirement for water used in animal drinking systems. A crystalline sucrose carrier below 40 μm is not used because it creates a viscous slurry that blocks nipple drinkers.

Where the required oral dose exceeds the flow capacity of the raw powder, fluid-bed granulation of Puqing Zhili Powder Veterinary Grade API is introduced. A bottom-spray Wurster insert is operated with a polyvinylpyrrolidone K30 5–10% w/v binder solution; inlet air temperature is held at 50–65 °C, product temperature at 30–40 °C, and spray rate at 10–20 g/min/kg of batch. The granules are dried to moisture below 3.0% and passed through a 1.0 mm oscillating mill. The resulting granules have a median particle size D50 200–500 μm and are blended with 0.2% w/w colloidal silicon dioxide before filling into stick packs or tubs. Flowability is measured by Ph. Eur. 2.9.16 using a 25 mm orifice; a flow rate below 10 g/s is rejected because it causes sticking on high-speed filling equipment. Granulation also reduces dust formation and masks bitter-tasting fractions of the API, which is important for oral dosing in calves and piglets when the product is top-dressed on feed or mixed into milk replacer. The granulation process is preferred over direct blending when the API contains fibrous particles or when static charge causes segregation in low-humidity environments below 20% RH.

When the API Is Dispersed in a 2% Mineral Premix Carrier for Feed Mill Integration

At feed mill scale, premix dilution of Puqing Zhili Powder Veterinary Grade API onto mineral carriers is used to produce a veterinary feed premix that is uniformly incorporated into complete feed at 0.5–2.0 kg/tonne. The carrier is calcium carbonate or ground rice hulls with a particle size between 250 μm and 800 μm; 1.0% w/w soy oil or mineral oil is added before the API to reduce dust and improve adhesion. Mixing is performed in a horizontal ribbon mixer with a working volume of 70–80% of nominal capacity at 20–30 rpm for 15–20 min. Homogeneity is verified by collecting 10 samples from different zones and measuring the marker compound relative standard deviation below 5.0%; sampling and acceptance follow 21 CFR 211.110 and the process validation requirements of EU GMP Part II Chapter 12. The finished premix is packed in multi-wall paper bags with an inner polyethylene liner at ≤50% RH and labeled for feed use. Carryover in the feed mill is validated to below 1.0% of the labeled dose for non-target feed lines. Maximum residue limits are checked under EU Regulation 37/2010 for food-producing species; if the product has no published MRL, it cannot be used in food-producing animals. The premix process is not interchangeable with direct oral powder blending because carrier segregation and electrostatic charges alter the content uniformity at low inclusion rates.

Oral solution pH-dependent degradation and preservative compatibility limits

In ready-to-use oral solutions, Puqing Zhili Powder Veterinary Grade API requires a buffered preservation system selected after antimicrobial effectiveness testing according to USP <51>/Ph. Eur. 5.1.3. The solution pH is fixed between 4.5 and 6.5 with a 10 mM citrate buffer; below pH 4.0 the API may form insoluble agglomerates, and above pH 7.0 oxidative degradation can occur in the presence of trace metal ions. The manufacturing vessel is a stainless steel tank with a bottom-mounted homogenizer operated at 3,000–5,000 rpm for 10–15 min, followed by passage through a 10 μm polypropylene bag filter. The solution is filled into amber PET bottles with tamper-evident caps and nitrogen-flushed to reduce headspace oxygen below 2.0% v/v. Sodium benzoate 0.1–0.2% w/w and potassium sorbate 0.1–0.2% w/w are added as preservatives, but compatibility with the API is tested because sorbate can form insoluble esters with alcohol-containing extraction fractions. Color change above 5.0% absorbance shift at the API λmax during stability storage at 15–25 °C indicates oxidative degradation and requires batch rejection. The finished solution is protected from light; freezing below 0 °C is avoided because ice crystals can disrupt the dispersed polysaccharide fraction and cause precipitation upon thawing.